PF-Atlas › Clinical Trials › NCT00656058

Montelukast to Treat Bronchiolitis Obliterans

Singulair · Phase 2

Registry ID

NCT00656058

Phase

Phase 2

Status

Completed

Drug / intervention

Singulair (Montelukast Sodium)

Sponsor

National Cancer Institute (NCI)

Start

2008-06-17

About this trial

Singulair is evaluated in NCT00656058, a Phase 2 idiopathic pulmonary fibrosis study sponsored by National Cancer Institute (NCI). Current status: Completed.

View NCT00656058 on ClinicalTrials.gov →

Explore related

All Singulair trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00656058 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.